KIT and solitary fibrous tumor: In addition, the multi-tyrosine kinase inhibitor pazopanib (VEGFRs, PDGFR, and cKit), that also has some modest efficacy against FGF signaling, was active as first-line therapy in metastatic SFT in a prospective study [46].